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Background: We have recently shown that T-antigen binding to Site I results in the replication-dependent
introduction of H3K9me1 into SV40 chromatin late in infection. Since H3K9me2 and H3K9me3 are also present
late in infection, we determined whether their presence was also related to the status of ongoing transcription
and replication. Transcription was either inhibited with 5,6-dichloro-1-beta-D-ribofuranosylbenzimidizole (DRB)
or stimulated with sodium butyrate and the effects on histone modifications early and late in infection determined.
The role of DNA replication was determined by concomitant inhibition of replication with aphidicolin.
Results: We observed that H3K9me2/me3 was specifically introduced when transcription was inhibited during
active replication. The introduction of H3K9me2/me3 that occurred when transcription was inhibited was partially
blocked when replication was also inhibited. The introduction of H3K9me2/me3 did not require the presence of
H3K9me1 since similar results were obtained with the mutant cs1085 whose chromatin contains very little
H3K9me1.
Conclusions: Our data suggest that methylation of H3K9 can occur either as a consequence of a specific repressive
event such as T-antigen binding to Site I or as a result of a general repression of transcription in the presence of
active replication. The results suggest that the nonproductive generation of transcription complexes as occurs following
DRB treatment may be recognized by a ‘proof reading’ mechanism, which leads to the specific introduction of
H3K9me2 and H3K9me3.Background
Five distinct but potentially related elements are thought
to contribute to the epigenetic regulation of eukaryotic
gene expression: DNA methylation, nucleosome loca-
tion, histone variation, covalent histone modifications,
and interactions by regulatory RNA. Of these elements,
the post-translational modification of histones has been
of particular interest because of the diversity of the avail-
able forms of modification and the number of target
amino acids and their physical location within histones.
Importantly, there is an abundance of published reports
demonstrating the association between certain forms
of histone modification and activation or repression of
transcription in one or more well characterized bio-
logical systems.* Correspondence: barry.milavetz@med.und.edu
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unless otherwise stated.In general, it is thought that acetylation of certain
lysines in histones is associated with active biological
processes like transcription while methylation of lysines
or arginines may be associated with either activation or
repression of gene transcription. For example, in the nu-
cleosome core, histone H3 acetylation on lysine 9 and 14
(H3K9 and H3K14) have been shown to be associated
with transcription along with methylation of lysine 4
(H3K4), while methylation of lysine 9 (H3K9) has been
shown to be associated with repression [1,2].
While the association between the methylation of H3K9
and gene repression has been well established, much less
is known about the circumstances that lead to the intro-
duction of methylated H3K9 into chromatin. What has
added to this uncertainty is the complexity of methylation,
including mono-, di-, and tri-methylation, and the involve-
ment of multiple methylating enzymes [3].
In order to better understand the factors that contrib-
ute to epigenetic regulation, we have been investigating
the role of histone modifications in the regulation ofal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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cycle [4-9]. In a recent publication we confirmed that
the mono-methylation of H3K9 in SV40 chromatin was
associated with repression of transcription [8]. Specific-
ally, we showed that the introduction of H3K9me1 was a
consequence of the repression of early transcription by
the product of transcription, T-antigen, binding to a critical
regulatory sequence known as Site I [8]. Moreover, import-
antly, we observed that the introduction of H3K9me1
during repression required DNA replication. Repression
occurring prior to the initiation of replication was not asso-
ciated with the introduction of H3K9me1. Our results
demonstrated that replication could serve as an epigenetic
switch and that the same biological event could have differ-
ent epigenetic readouts depending upon whether replica-
tion was occurring.
During the course of these studies, we investigated the
introduction of all three methylated forms of H3K9 dur-
ing replication. We noted that unlike the introduction of
H3K9me1 which absolutely required replication, the
introduction of H3K9me2 and H3K9me3 appeared to
occur even when replication was substantially blocked
by inhibitor [8]. These results raised two important
questions. First, was the introduction of H3K9me2 and
H3K9me3 also associated with the repression of tran-
scription in SV40 chromatin, and second, what bio-
logical factors contributed to the introduction of these
epigenetic marks?
In order to address these questions in SV40 chromatin,
we have investigated the effects of a general inhibition or
stimulation of transcription on the introduction of H3K9
methylation in the presence or absence of active replication.
Transcription was inhibited with 5,6-dichloro-1-beta-D-
ribofuranosylbenzimidizole (DRB) [10], a well-characterized
inhibitor of RNA Polymerase II (RNAPII) elongation, and
stimulated with sodium butyrate, an inhibitor of histone
deacetylase [11,12] known to stimulate gene expression.
DNA replication was inhibited with aphidicolin [13]. We
show that the introduction of H3K9me2 and H3K9me3 are
the result of a general inhibition of transcription at late
times in infection but not early times, and that the intro-
duction is partially dependent upon replication but not the
prior introduction of H3K9me1.
Results
Inhibition of transcription by DRB stimulates the
introduction of H3K9me2 and H3K9me3 into SV40
chromatin late in infection but not early in infection
Since we previously observed that the introduction of
H3K9me2 and H3K9me3 was not directly related to re-
pression by T-antigen binding to Site I [8], we hypothe-
sized that their incorporation into SV40 chromatin
might be the consequence of a more general inhibition
of transcription. In order to test this hypothesis wedetermined the epigenetic consequences of inhibiting
transcription with the RNAPII elongation inhibitor 5,6-
dichloro-1-beta-D-ribofuranosylbenzimidizole (DRB). We
have previously used DRB to investigate the relationship
between RNA polymerase II translocation and the acetyl-
ation and deacetylation of histones during transcription
[7]. For these studies, we chose to investigate SV40 chro-
matin isolated at 2 hours post-infection when early tran-
scription was occurring but prior to DNA replication, and
at 48 hours post-infection when early and late transcrip-
tion were occurring along with active replication.
SV40 minichromosomes were isolated and purified
from cells infected with wild-type 776 virus following
treatment with DRB or no treatment. When minichro-
mosomes were isolated at 2 hours, cells were pretreated
with DRB for 2 hours prior to infection, while for mini-
chromosomes isolated at 48 hours post-infection in-
fected cells were treated from 24 to 48 hours. In these
experiments, we observed a 112 ± 35 fold increase in the
size of the pool of SV40 chromosomes present in gly-
cerol gradient fractions following purification from cells
infected for 48 hours compared to 24 hours post-
infection. While the increase was somewhat variable we
always observed at least a tenfold increase. This increase
was reduced 10 ± 6 fold following treatment of the SV40
infected cells with DRB from 24 to 48 hours post-
infection. The latter analysis was determined by compar-
ing the increase in the presence and absence of inhibitor
and indicates that on average there was about a ten-
fold reduction in the pool of SV40 minichromosomes
following inhibition. As expected, treatment with DRB
substantially inhibited the generation of mRNA (data
not shown).
The effect of DRB on the introduction of methylated
H3K4 and H3K9 was determined by subjecting treated
and untreated samples of intact SV40 minichromosomes
obtained at 2 hours and 48 hours post-infection to ChIP
analyses with antibodies that recognize mono-, di-, or
tri-methylated H3K4 or H3K9. Intact SV40 minichromo-
somes were used because they are easily obtained in
relatively large amounts and yield the maximum PCR
signal compared to fragmented chromatin. Because the
SV40 genome was intact, this analysis only yielded infor-
mation relative to changes in the numbers of minichro-
mosomes carrying a particular modification following
treatment. No information was obtained concerning the
location of any specific histone modifications. The re-
sults of these analyses are graphically shown in Figure 1.
The data is displayed as the ratio of the percentage of
minichromosomes that contain a modification following
treatment divided by the percentage of untreated mini-
chromosomes containing the same modification. If treat-
ment had no effect on the introduction of a particular
modification the ratio will be one. Ratios greater than
Figure 1 Inhibition of transcription with 5,6-dichloro-1-beta-D-ribofuranosylbenzimidizole (DRB) stimulates the incorporation of
H3K9me2 and H3K9me3 into SV40 chromatin late in infection. Wild-type SV40 minichromosomes were isolated at 2 hr post-infection with or
without incubation with 5,6-dichloro-1-beta-D-ribofuranosylbenzimidizole (DRB) from minus 2 hr until isolation and at 48 hr post-infection with or
without incubation with DRB from 24 to 48 hr post-infection. The percentages of intact minichromosomes containing methylated H3K4 and
H3K9 were determined by ChIP analyses followed by purification of the intact genomic DNA and PCR amplification with primers recognizing the
promoter region. For each form of histone modification, the ratio of the percentage present in the treated minichromosomes compared to the
untreated minichromosomes was calculated. The effects of DRB treatment on the introduction of methylated H3K4 and H3K9 from minus 2 hr to
isolation at 2 hr post-infection is shown in (A). The corresponding effects of DRB treatment on the introduction of methylated H3K4 and H3K9
from 24 to 28 hr post-infection are shown in (B).
Figure 2 The 5,6-dichloro-1-beta-D-ribofuranosylbenzimidizole
(DRB)-stimulated introduction of H3K9me2 and H3K9me3 is
partially dependent upon ongoing DNA Replication. Wild-type
SV40 minichromosomes were isolated at 48 hr post-infection with or
without treatment with 5,6-dichloro-1-beta-D-ribofuranosylbenzimidizole
(DRB) and aphidicolin from 24 to 48 hr post-infection. The treated and
untreated intact minichromosomes were subjected to ChIP analyses
with antibodies to H3K9me2 and H3K9me3 and the percentages of
the minichromosomes containing the modified H3K9s determined
by real-time PCR amplification of the bound intact SV40 genomic
DNA with primers recognizing the promoter region. The fold increase
in the percentages of minichromosomes containing H3K9me2 and
H3K9me3 was then calculated.
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minichromosomes containing the modification while ra-
tios less than one indicate that treatment resulted in a
decrease in the presence of a modification.
As shown in Figure 1A and B, DRB treatment had no
significant effect on the methylation of H3K4 at either
2 hours or 48 hours post-infection. For each form of
methylation, the ratio of treated sample to untreated
sample was approximately one. In contrast, DRB treat-
ment had a significant effect on the presence of
H3K9me2 and H3K9me3 at 48 hours post-infection
and little effect at 2 hours post-infection (Figure 1A
and B). We observed a 6 ± 4 fold increase for H3K9me2
with a range from 3 to 12 for four independent samples
and a 6 ± 2 fold increase for H3K9me3 with a range of
3 to 8 for four independent samples. As expected from
our previous published work, DRB treatment had no
significant effect on the presence of H3K9me1 at either
time point.
Introduction of H3K9me2 and H3K9me3 following
inhibition of transcription is partially dependent upon
replication
Since we have previously shown that the introduction of
H3K9me2 and H3K9me3 into SV40 chromatin late in
infection does not require DNA replication [8], we next
tested whether replication played a role in the enhanced
introduction of these modifications following DRB inhib-
ition of transcription. SV40 minichromosomes were ob-
tained from infected cells that were untreated or treated
from 24 to 48 hours post-infection with a combinationof DRB and aphidicolin to inhibit both transcription and
replication. The minichromosomes were then subjected to
ChIP analyses with antibody to H3K9me2 and H3K9me3
with the results shown in Figure 2. The data is again
shown as the ratio between the percentages of input
Figure 3 The 5,6-dichloro-1-beta-D-ribofuranosylbenzimidizole
(DRB)-stimulated introduction of H3K9me2 and H3K9me3 does not
require the presence of H3K9me1. SV40 minichromosomes from the
mutant virus cs1085 were isolated at 48 hr post-infection with or without
treatment with 5,6-dichloro-1-beta-D-ribofuranosylbenzimidizole (DRB)
from 24 to 48 hr post-infection. Intact minichromosomes were
subjected to ChIP analyses with antibody recognizing H3K9me2
and H3K9me3 and the intact SV40 genomic DNA present in
the bound fraction quantitated by real-time PCR with primers
recognizing the promoter region. The percentages of minichromosomes
in the treated and untreated samples were determined and the fold
increase in the percentage in the treated samples compared to the
untreated calculated.
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in the treated sample compared to the untreated sample.
Treatment with aphidicolin and DRB resulted in ap-
proximately a 99% reduction in the amount of SV40
minichromsomes obtained at 48 hours post-infection
compared to the amount obtained from untreated cells.
Following inhibition we observed no increases in the ratio
for H3K9me2 (1 ± 0.5) and a small increase in the ratio for
H3K9me3 (2 ± 1). These increases were significantly lower
than the values obtained when transcription was inhibited
while DNA replication was occurring as shown in Figure 1.
These results suggest that ongoing replication plays at
least a small role in the introduction of H3K9me2 and
H3K9me3 at late times in infection.
Introduction of H3K9me2 and H3K9me3 following
inhibition of transcription does not require the presence
of H3K9me1
Since H3K9me1 can be present in as much as 22% of
the SV40 minichromosomes present at late times [9], it
seemed reasonable that the H3K9me1 containing mini-
chromosomes might serve as substrates for the introduc-
tion of H3K9me2 and H3K9me3. To test this possibility
we characterized the effect of DRB treatment on the
mutant cs1085 SV40 virus. This mutant lacks T-antigen
binding Site I and as a consequence fails to down-
regulate early transcription. We have previously shown
that minichromosomes from this mutant contain very
low levels of H3K9me1in contrast to parental wild-type
viral chromatin [9]. If the minichromosomes containing
H3K9me1 served as a substrate for the introduction of
H3K9me2 and H3K9me3, we would expect that inhib-
ition of transcription of cs1085 with DRB would not re-
sult in a large increase in the amounts of H3K9me2 and
H3K9me3 in the treated minichromosomes compared to
the untreated minichromosomes.
Cells infected with SV40 cs1085 virus were treated with
DRB from 24 to 48 hours post-infection or left untreated
and the minichromosomes present in the cells isolated and
purified. The minichromosomes were subjected to ChIP
analyses with antibodies to H3K9me2 and H3K9me3 with
the results shown in Figure 3. Treatment with DRB resulted
in significant increases in the amounts of H3K9me2 (3 ± 1
fold) and H3K9me3 (5 ± 3 fold) present in the cs1085 mini-
chromosomes indicating that the presence of H3K9me1 in
the minichromosomes was not necessary for the introduc-
tion of the higher levels of methylated H3K9.
Introduction of H3K9me2 and H3K9me3 are associated
with SV40 minichromosomes that contain RNAPII
In order to determine whether H3K9me2 and H3K9me3
were being added to minichromosomes that contain
RNAPII following treatment with DRB, we analyzed
SV40 minichromosomes that contain RNAPII for thepresence of the two methylated forms of H3K9 following
treatment with DRB using our ISFIP procedure [4,5].
In this procedure, SV40 minichromosomes containing
RNAPII were immune-selected with antibody to RNAPII
bound to protein A agarose in a standard ChIP assay. Fol-
lowing purification of the bound chromatin and prior to
elution, the minichromosomes bound to agarose were
sonicated to fragment the chromatin into nucleosome-
sized pieces and the bound fragments separated from the
released fragments. The released fragments were then
subjected to a second ChIP with antibodies to H3K9me2
and H3K9me3 to determine whether H3K9me2 and
H3K9me3 were present in the minichromosomes contain-
ing RNAPII and if so whether the amount changed upon
treatment with DRB.
As shown in Figure 4 we observed increases in the per-
centage of the RNAPII containing minichromosomes
which also contained H3K9me (2 ± 1 fold) and H3K9me3
(3 ± 2 fold) although not as significant as those observed in
Figure 1. These results suggest that minichromosomes
containing RNAPII may serve as the substrate for H3K9
methylation.
Stimulation of transcription with sodium butyrate inhibits
the incorporation of H3K9me2 and H3K9me3 into SV40
chromatin late in infection
Since the introduction of H3K9me2 and H3K9me3 ap-
peared to be associated with repression of transcription,
Figure 4 The 5,6-dichloro-1-beta-D-ribofuranosylbenzimidizole
(DRB)-stimulated introduction of H3K9me2 and H3K9me3 is
partially associated with minichromosomes containing RNAPII.
Wild-type SV40 minichromosomes were isolated from cells at 48 hr
post-infection with or without treatment with 5,6-dichloro-1-beta-D-
ribofuranosylbenzimidizole (DRB) from 24 to 48 hr post-infection. Intact
Minichromosomes were subjected to an ISFIP ChIP analysis in which
minichromosomes were first immune selected with antibody to RNAPII.
The minichromosomes bound by antibody to RNAPII were sonicated
and the soluble chromatin fraction subjected to a second ChIP with
antibody to either H3K9me2 or H3K9me3. The percentage of the
treated and untreated chromatin containing H3K9me2 and
H3K9me3 was determined by real-time PCR using primers that
recognize the early region of the genome and the fold increase
resulting from treatment calculated.
Figure 5 The introduction of H3K9me2 and H3K9me3 is
inhibited by sodium butyrate stimulation of transcription
during active replication. Wild-type SV40 minichromosomes
were isolated at 12 hr post-infection with or without treatment
from the initiation of infection with sodium butyrate and at 48 hr
post-infection with or without treatment with sodium butyrate
from 24 to 48 hr post-infection. Intact minichromosomes isolated
at 12 hr post-infection were subjected to ChIP analyses with
antibodies to methylated H3K9. Intact minichromosomes isolated
at 48 h post-infection were subjected to ChIP analyses with
antibodies to methylated H3K4 and methylated H3K9. The percentage of
treated and untreated minichromosomes containing each form of
methylated H3K4 or H3K9 was determined by real-time PCR
amplification of the intact SV40 genomic DNA with primers
recognizing the promoter region. The fold change resulting from
treatment was then calculated from the percentages.
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would have the opposite effect. Sodium butyrate is a
well-known inhibitor of many histone deacetylases and
for this reason has been used extensively to investigate
the relationship between histone acetylation and various
biological processes including transcription [11,12]. We
have previously shown that inhibition of histone deace-
tylases by sodium butyrate results in an increase in tran-
scription of actively transcribed genes as well as an
increase in histone acetylation [6,14]. If increased tran-
scription and/or histone acetylation prevented the intro-
duction of H3K9me2 or H3K9me3, we would expect to
see a reduction in the ratio of these two modified forms
of H3 in the treated minichromosomes compared to the
untreated minichromosomes.
SV40 wild-type infected cells were harvested at 24 hours
post-infection, 48 hours post-infection, or 48 hours post-
infection following treatment with 50 μM sodium butyrate
from 24 to 48 hours post-infection to determine the effects
of sodium butyrate during the period of active replication.
In a parallel analysis, infected cells were harvested at
12 hours post-infection and 12 hours following a 12-hour
treatment with sodium butyrate to determine the effects of
sodium butyrate in the absence of replication. The mini-
chromosomes were purified and subjected to ChIP analyses
with antibodies to methylated H3K4 and H3K9 withminichromosomes isolated late in infection but only meth-
ylated H3K9 when isolated at very early times. The reason
for this was our previous observation that relatively little of
the SV40 chromatin contained methylated H3K4 at the
very early times [9] and because there was no change in the
levels of methylated H3K4 following DRB treatment. As
shown in Figure 5, we observed ratios close to 1 for
H3K9me1 (0.9 ± 0.1) and H3K9me3 (1.5 ± 0.8) in minichro-
mosomes isolated at 12 hours post-infection. We saw
very low levels of H3K9me2 in both treated and untreated
minichromosomes, which were too variable to quantitate
at this time. In contrast, for minichromosomes isolated at
48 hours post-infection, we observed significant inhibition
of H3K9 methylation. The ratios were 0.46 ± 0.13 for
H3K9me1, 0.08 ± 0.04 for H3K9me2, and 0.39 ± 0.2 for
H3K9me3. While H3K4me2 (0.75 ± 0.13) and H3K4me3
(1.26 ± 0.38) did not seem to be affected by sodium
butyrate treatment at late times, H3K4me1 (0.47 ± 0.27)
appeared to be moderately inhibited (data not show). The
decrease in the levels of H3K9me2 and H3K9me3 when
transcription was stimulated were consistent with the idea
that these modifications were being introduced as a conse-
quence of a general repression of transcription at late
times.
Figure 6 The pool size of SV40 minichromosomes containing
RNAPII is dynamic and dependent upon replication and rate of
transcription. SV40 minichromosomes were isolated from cells
infected with wild-type virus at 24 and 48 hr post-infection. Infected cells
were either untreated or treated from 24 to 48 hr post-infection with
DRB, sodium butyrate (NaBt), or aphidicolin. Intact minichromosomes
were subjected to ChIP analyses with antibody to RNAPII and the
percentage of untreated and treated minichromosomes containing
RNAPII was determined by real-time PCR amplification of the intact SV40
genomic DNA with primers recognizing the promoter region. The fold
increase or decrease from 24 to 48 hr post-infection with or without
treatment was then calculated from the percentages.
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dynamic during replication
Since DRB had a major effect on transcription and the
introduction of H3K9me2 and H3K9me3, we also deter-
mined whether it affected the proportion of minichromo-
somes carrying RNAPII and was, therefore, potentially
capable of transcription. We have previously shown that
with short-term treatment with DRB there was little effect
on the percentage of minichromosomes carrying RNAPII
[7]. However, long-term treatment when replication was
occurring could be different. In order to better understand
the factors contributing to determining the pool size of
minichromosomes containing RNAPII during this time
frame, we also investigated the effects of aphidicolin and
sodium butyrate. If the pool of minichromosomes contain-
ing RNAPII was simply related to the overall size of the
pool of minichromosomes, we would expect to observe
that the percentage containing RNAPII would remain
constant despite the overall changes in the size of the pool
following the different treatments. For this analysis, we
compared the percentage of RNAPII containing minichro-
mosomes at 24 hours post-infection when replication was
beginning to 48 hours post-infection when replication was
active in the presence or absence of the replication inhibi-
tor aphidicolin, transcription inhibitor DRB, or transcrip-
tion stimulator sodium butyrate.
As indicated above, between 24 and 48 hours post-
infection we observed a 112 ± 35 fold increase in the size
of the minichromosome pool. Following treatment with
aphidicolin the pool size at 48 hours post-infection was
essentially the same as at 24 hours post-infection indi-
cating substantial inhibition by the drug. Following treat-
ment with DRB we again observed a substantial increase
in the pool of minichromosomes although the increase
was 10 ± 6 fold less than observed in the absence of the
inhibitor. Treatment with sodium butyrate was seen
to increase the size of the pool of minichromosomes
by 10 ± 4 fold above the level of increase without the
added sodium butyrate. The latter two results indicate
that the inhibitors had a modest effect on pool sizes
when replication was occurring.
SV40 minichromosomes from treated or untreated
infections were subjected to ChIP analysis with antibody
to RNAPII with the results shown in Figure 6. We ob-
served that the ratio of the percentage of minichromo-
somes containing RNAPII was only 0.14 ± 0.04 comparing
minichromosomes isolated at 48 hours post-infection to
24 hours post-infection indicating that only a small
fraction of the newly replicated minichromosomes became
associated with RNAPII. Following treatment with aphidi-
colin to block replication the ratio was reduced even fur-
ther. Compared to untreated controls at 48 hours the ratio
was 0.64 ± 0.16. Since there was no increase in the overall
pool size this indicated that the actual amount of SV40chromatin containing RNAPII following inhibition of rep-
lication was lower in the treated samples than was present
at 24 hours post-infection. Following treatment with DRB
from 24 to 48 hours post-infection the ratio of minichro-
mosomes containing RNAPII increased to 1.2 ± 0.5, indi-
cating that the pool size of transcribing minichromosomes
was increasing along with replication in the presence of
DRB. Finally, we observed that treatment with sodium bu-
tyrate during replication also had a profound effect. The
ratio of RNAPII containing minichromosomes was 0.39 ±
0.20 following treatment with sodium butyrate from 24 to
48 hours post-infection. This indicated that compared to
untreated controls a larger fraction of minichromosomes
were capable of transcription.
Discussion
The introduction of H3K9me2 and H3K9me3 into SV40
chromatin following repression of transcription through
the inhibition of RNAPII elongation by the inhibitor DRB
is consistent with previous reports showing that the pres-
ence of H3K9me2 and H3K9me3 in chromatin is associ-
ated with transcriptional repression (reviewed in [15,16]).
H3K9me3, in particular, is now considered a characteristic
mark of repression by many laboratories [2].
H3K9me2 and H3K9me3 are typically introduced into
chromatin by a member of the SET domain family of his-
tone methyltransferases [16]. The related proteins G9a
and GLP are thought to be primarily responsible for
H3K9me2 methylation in euchromatin, whereas Suv39H1
is thought to be responsible for H3K9me3 methylation in
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able of introducing H3K9me3 into euchromatin [20].
While these proteins contribute to the bulk of the
H3K9me2 and H3K9me3 in a cell, there are other methyl-
tranferases that may also play a role since deletion of these
enzymes cause a significant but not complete reduction in
H3K9 methylation [16].
There are two well-characterized mechanisms for the
introduction of H3K9me2 and H3K9me3. H3K9me2 is
associated with repression of nuclear hormone receptor
regulated transcription (reviewed in [15]). In this model
system, the introduction of H3K9me2 is the consequence
of the binding of the receptor along with the histone
methyltransferase to maintain a repressive environment.
Introduction of the ligand results in the selective loss of
the methyltranferase and subsequent corresponding loss
of H3K9me2 and activation of transcription [15].
The introduction of H3K9me3 into heterochromatin
has also been extensively characterized (reviewed in
[21]). The introduction of H3K9me3 in heterochromatin
is thought to be closely linked with replication and to
occur through the targeting of the relevant methyltran-
ferase by associated proteins including CAF1, HP1, and
MBD1 in higher eukaryotes [22,23] and Clr4 and Swi6
in fission yeast [21]. The presence of MBD1 in higher
eukaryotes links H3K9me3 to DNA methylation and
suggests a possible mechanism for targeting the complex
to the appropriate sites (hemi-methylated DNA) follow-
ing replication.
It seems unlikely that either of these mechanisms is
responsible for the introduction of H3K9me2 and
H3K9me3 reported here. With respect to the introduc-
tion of H3K9me2, SV40 transcription does not appear to
be regulated by a nuclear hormone type mechanism as
previously described for H3K9me2. Similarly the ob-
served increase in H3K9me2 occurred as a consequence
of the inhibition of transcription by DRB not the binding
of normal transcription factors. The introduction of
H3K9me3 also is unlikely to occur by the same mechan-
ism as described for heterochromatin. Notably, SV40
DNA in chromatin is not known to be methylated be-
cause of an absence of DNA methylase substrates in the
DNA. Also our observed increase in H3K9me2 and
H3K9me3 appeared to be only secondarily a result of
DNA replication since the increase was observed on
minichromosomes containing RNAPII.
To explain our results we propose the following model.
As DNA replication takes place, some of the newly repli-
cated minichromosomes are committed to transcription
through the binding of specific and general transcription
factors. Concurrently, for reasons as yet unknown, some
of the preexisting transcribing minichromosomes stop
transcription. These nonfunctioning minichromosomes
are recognized as being repressed, and H3K9me2 andH3K9me3 are introduced into their chromatin as a mark
of repression. We propose that following replication and
the activation for new transcription there is a ‘proofread-
ing mechanism,’ which ensures that the newly initiated
minichromosomes are capable of productive transcription.
In the event that this is not the case, the minichromo-
somes are again recognized as repressed, as with the non-
functioning minichromosomes, and marked by H3K9me2
and H3K9me3. Since treatment with the inhibitor DRB
results in a large increase in the number of minichromo-
somes in which transcription is stopped, presumably at
initiation, there is a corresponding increase in the incorp-
oration of H3K9me2 and H3K9me3.
This proofreading mechanism could be specific to
SV40 and other similar viruses in which case it could
function to ensure that the size of the pool of transcrib-
ing minichromosomes is tied to the level of replication
and encapsidation. Conversely, this mechanism could be
true for higher eukaryotes in general and serve as a way
to ensure that when genes are activated for transcription,
only those genes correctly activated are allowed to per-
sist in the activated state.
Assuming that the introduction of H3K9me2 and
H3K9me3 following the inhibition of elongation by
RNAPII reflects a normal biological process for SV40,
we believe it is likely to play a role in two aspects of nor-
mal SV40 molecular biology. First, the introduction of
H3K9me2 and H3K9me3 could play a critical role in
regulating the pool size of transcriptionally competent
minichromosomes during an infection. We have pre-
sented evidence that the pool size is dynamic with new
transcribing minichromosomes entering the pool as a re-
sult of replication and old minichromosomes leaving the
pool. We believe that old minichromosomes leaving the
pool of transcribing minichromosomes would be labeled
with H3K9me2 and H3K9me3 in order to prevent their
reactivation.
Second, H3K9me2 and H3K9me3 could also play a
critical role during the initiation of a subsequent infec-
tion. We have shown that minichromosomes in virions
contain significant amounts of H3K9me2/3 [9]. If the
minichromosomes, which contain these modifications,
result primarily from the minichromosomes that originally
transcribed the late genes following replication, it seems
desirable that they be silenced during a new infection
when only the transcription of the early genes is required.
Allowing transcription of the late genes during the
establishment of an infection would seem to be very
undesirable for the virus.
Because DRB treatment blocks RNAPII elongation, we
believe that it is a way to model the effects of repression
of transcription in order to characterize the subsequent
changes in epigenetic modifications. However, we recognize
that the DRB treatment, as well as the treatment with the
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served effects on the levels of H3K9me2 and H3K9me3
and may not accurately reflect the epigenetic changes
occurring in vivo.
Conclusions
Methylation of H3K9 can occur during active expression
either as a consequence of a specific repressive event
such as T-antigen binding to Site I or as a result of a
general repression of transcription. Moreover, these re-
sults suggest that the nonproductive transcription com-
plexes which are generated by DRB treatment may be
recognized by a ‘proof reading’ mechanism, which leads
to the specific introduction of H3K9me2 and H3K9me3.
Methods
Cells and viruses
Wild-type and mutant SV40 minichromosomes were pre-
pared in the monkey kidney BSC-1 cell line (ATCC) using
either wild-type 776 virus (from Dr. Daniel Nathans) or
cs1085 virus (from Dr. Daniel Nathans).
Cell culture and infections
BSC-1 cells were maintained and infected as previously
described [5-7]. An RNA polymerase II inhibitor, 5,6-
dichloro-1-beta-D-ribofuranosylbenzimidizole (DRB), was
used at a concentration of 200 μM. For 2-hour infections,
DRB was added two hours prior to infection and re-
applied at 30 minutes post-infection when the media was
replaced by fresh media without virus. For 48-hour infec-
tions, DRB was added at 24 hours post-infection. Sodium
butyrate was used at a concentration of 250 μM. Sodium
butyrate was added at infection and along with fresh
media following removal of unbound virus for 12-hour
infections and at 24 hours post-infection for 48-hour in-
fections. Replication was inhibited with aphidicolin added
at 24 hours post-infection at a final concentration of 6 μM
as previously described [8].
Preparation of SV40 minichromosomes
SV40 minichromosomes were isolated at the indicated
times from 2 hours to 48 hours post-infection as de-
scribed for each of the analyses using our standard puri-
fication protocols [5-7] with one minor modification.
After transferring the lysed cells to a 15-ml centrifuge
tube, an additional one ml of nuclei preparation buffer
was used to rinse the flask and was subsequently added
to the centrifuge tube in order to maximize the yield of
minichromosomes from each infection.
Chromatin immunoprecipitation
ChIP kits were obtained from Millipore (Temicula,
California, USA) and the protocol was followed aspreviously described [8]. The antibodies used in-
cluded: H3K4me1 (07 = 436, Millipore (Temicula,
California, USA), H3K4me2 (39141, Active Motif
Carlsbad, California, USA), H3K4me3 (04 = 745, Millipore
Temicula, California, USA), H3K9me1 (ab9045, Abcam,
Cambridge Massachusetts USA), H3K9me2 (ab1220,
Abcam, Cambridge, Massachusetts, USA), H3K9me3
(ab8898, Abcam, Cambridge, Massachusetts, USA), and
RNA PII 905 = 623, Millipore,Temicula, California, USA).
All antibodies were ChIP validated by the respective
vendors. A total of 100 μl of Protein A agarose, 800 μl chip
dilution buffer, and 7.5 μl of each antibody were combined
in a protein low-bind tube. The mixture was rotated for
5 hours at 4°C on an end to end rotator in a refrigerator to
bind the antibody to Protein A agarose. Following binding
of the antibody, the Protein A agarose was centrifuged at
2,000 rpms for 2 minutes and the supernatant discarded.
Next, 800 μl of fresh ChIP dilution buffer was added, and
100 μl of the SV40 chromatin to be analyzed was added.
The samples containing antibody bound to Protein A agar-
ose and chromatin were incubated with end to end rota-
tion for a further 7 hours at 4°C. The chromatin bound to
Protein A agarose was washed according to the manufac-
turer’s protocol and eluted as previously described [8].
Immune selection fragmentation immunoprecipitation
ChIPs were performed as previously described [5-7] with
the following changes. The amount of input chromatin
added was increased to 200 μl and the amount of Pro-
tein A agarose was doubled to 200 μl. Following the final
wash of the protein A agarose containing antibody and
bound chromatin, the agarose was resuspended in
200 μl of buffer and transferred to a clean low-bind
Eppendorf centrifuge tube. The suspension was soni-
cated using a Branson Digital Sonifier for 6 minutes with
the amplitude set at 50%. The sonicated samples were
centrifuged at 2,000 rpms for 2 minutes to separate the
chromatin that remained bound to the agarose from the
fragmented chromatin in the supernatant and the super-
natant chromatin saved. The chromatin that remained
bound to agarose following sonication was removed with
lysis buffer according to the ChIP kit’s instructions. The
supernatant was then used as the starting material for a
subsequent ChIP.
Preparation of DNA: Samples were prepared for PCR
using an MP Bioscience (Solon, Ohio, USA) Geneclean
Spin Kit (#111101-200) with the following modifications.
The glassmilk reagent (100 μl) was mixed with 50 μl of
sample in a 1.5-ml centrifuge tube. The tube was mixed
by repeated inversion at 2 minutes and again at 4
minutes of incubation. Following 5 minutes of room
temperature incubation, the samples were centrifuged at
6,000 rpm for 30 seconds in a Micro One (Tomy) to pel-
let the glass. The supernatant was discarded and 200 μl
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buffer was being added, the pipette tip was used to break
up the pellet by physically rubbing the pellet and vigor-
ously pipetting up and down. The samples were inverted
twice and centrifuged at 6,000 rpm for 30 seconds to
again pellet the glass. The supernatant was discarded
and the pellets were dried in a vacuum for 5 minutes.
The glass pellet with bound DNA was resuspended in
25 μl Tris EDTA (TE) buffer.
PCR amplification
For most of the amplifications, DNA was amplified from
the promoter region of the SV40 genome using the
primers 5′ TTG CAA AAG CCT CCA AA 3′ and 5′
TGA CCT ACG AAC CTT AAC CGA GGG 3′ in a CFX
Connect Real Time System thermal cycler (Bio-Rad,
Ipswich, Massachusetts, USA) using ‘SSO Advanced
DNA polymerase (Bio-Rad, Ipswich, Massachusetts, USA).
In the immune selection fragmentation experiment, DNA
was amplified from the early region using the primers 5′
TGCTCCCATTCATCAGTTCC3′ and 5′CTGACTTTG
GAGGCTTCTGG3′ because the promoter region is
extremely sensitive to sonication. Immediately before use,
the primers and DNAse free water were added, and 28 μl
of the mix was used per sample. 2 μl of the resuspended
glass milk in TE buffer was added per sample. Samples
were amplified by PCR in triplicate with a melt curve
applied afterwards to ensure specific amplification. All
sample preparation for PCR was done in either a Nuaire
biological safety cabinet Model NU_425-400 or an
AirClean 600 PCR Workstation (ISC BioExpress).
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